Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s Disease

Advances in pharmacogenetics of anti-Parkinson's drugs treatment

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics

Genetics in Parkinson’s disease, state-of-the-art and future perspectives

An Update on Potential Therapeutic Strategies for Parkinson’s Disease Based on Pathogenic Mechanisms

Genetics of Parkinson's Disease: state-of-the-art and role in clinical settings

A Review of Genetic and Gene Therapy for Parkinson’s Disease

Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine

Advances in targeted therapies for Parkinson's disease

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

Identification of Parkinson’s Disease PACE Subtypes and Repurposing Treatments Through Integrative Analyses of Multimodal Data

The genetic background of Parkinson's disease: current progress and future prospects

Genetic risk factors in Parkinson’s disease

Parkinson disease therapy: current strategies and future research priorities

Parkinson’s disease: etiopathogenesis and treatment

Gene–environment Interactions: Key to Unraveling the Mystery of Parkinson's Disease

Diagnosis and treatment of Parkinson disease: molecules to medicine

Emerging targets and new small molecule therapies in Parkinson’s disease treatment

Identifying Genetic Targets in Clinical Subtypes of Parkinson’s Disease for Optimizing Pharmacological Treatment Strategies

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Recent advances in novel mutation genes of Parkinson's disease